Analyst Reco. LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
5.57 ^USD	-.--%		-2.28%	-28.86%

29/05	Lifestance Health Group Insider Sold Shares Worth $22,395,812, According to a Recent SEC Filing	MT
29/05	Lifestance Health Group Insider Sold Shares Worth $9,569,118, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lifestance Health Group Insider Sold Shares Worth $22,395,812, According to a Recent SEC Filing	30/05	MT
Lifestance Health Group Insider Sold Shares Worth $9,569,118, According to a Recent SEC Filing	30/05	MT
LifeStance Health Group Prices Secondary Stock Offering; Shares Plunge Premarket	22/05	MT
LifeStance Health Discloses Secondary Public Offering	22/05	MT
Lifestance Health Group Insider Sold Shares Worth $362,567, According to a Recent SEC Filing	15/05	MT
Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating	06/03	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating	04/03	MT
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating	29/02	MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating	29/02	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $8 From $9, Maintains Neutral Rating	22/11	MT
JPMorgan Adjusts LifeStance Health Group's Price Target to $8 From $10, Maintains Neutral Rating	17/11	MT
UBS Cuts LifeStance Health Group's Price Target to $7 From $10, Keeps Neutral Rating	09/11	MT
Goldman Sachs Adjusts LifeStance Health Group's Price Target to $9 From $8, Keeps Neutral Rating	19/23/19	MT
UBS Adjusts LifeStance Health Price Target to $10 From $7, Maintains Neutral Rating	12/23/12	MT
Morgan Stanley Adjusts Price Target on LifeStance Health to $10 From $8, Maintains Overweight Rating	11/23/11	MT
UBS Adjusts Price Target on LifeStance Health to $7 From $6.50, Maintains Neutral Rating	09/23/09	MT
Morgan Stanley Upgrades LifeStance Health Group to Overweight From Equalweight With $8 Price Target	06/23/06	MT
Goldman Sachs Trims Price Target on LifeStance Health Group to $8 From $9, Maintains Neutral Rating	15/22/15	MT
Cowen Trims Price Target on LifeStance Health Group to $8 From $10, Maintains Outperform Rating	14/22/14	MT
UBS Adjusts LifeStance Health Group Price Target to $6.50 From $7, Maintains Neutral Rating	09/22/09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Analyst Reco.

Filters